The PFD enabled accurate and high-resolution dose measurements on the curved surfaces of Ru-106 plaques. Both planar and CAX measurements demonstrated strong agreement with manufacturer-certified reference data across all plaque types. This system offers a practical and reproducible solution for commissioning and QA in Ru-106 plaque brachytherapy, supporting its clinical integration for choroidal melanoma treatment.
Cho et al. (2026) studied this question.